A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2019
Price : $35 *
At a glance
- Drugs ADCT-601 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors ADC Therapeutics
- 16 Jan 2019 According to an ADC Therapeutics media release, the first patient has been dosed in this study.
- 16 Jan 2019 Status changed from not yet recruiting to recruiting, according to an ADC Therapeutics media release.
- 12 Oct 2018 New trial record